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SUMOylation of PML–RARa oncoprotein has been linked to its arsenic-induced degradation and the 
therapeutic response in acute promyelocytic leukaemia. Two groups identify PML as an in vivo target 
of the RING finger ubiquitin E3 ligase RNF4, which specifically binds polySUMOylated PML and is 
essential for the arsenic-induced catabolism of both PML and PML–RARa. 
Although better known as a poison and famously rumoured to have been used to kill Napoleon, arsenic is 
one of the oldest medicines known to man. First described nearly 2500 years ago by the ancient Greek 
physician Hippocrates, it has been used to treat a variety of ailments and diseases including syphilis and 
cancer (for a review see ref. 1). The use of arsenic declined during the twentieth century due to concerns 
about its toxicity and advances in modern medicine. However, in 1992 it was reported that Ai-ling 1, a 
Chinese traditional medicine containing high levels of this semi-metal induced dramatic remissions in 
patients suffering from acute promyelocytic leukaemia (APL). Arsenic trioxide (ATO, As2O3) was identified as 
the active component and the finding that it was therapeutically effective in APL but not in other subtypes of 
acute myeloid leukaemia suggested that it targeted the PML–RARa fusion oncoprotein, which exerts a 
dominant-negative effect on both retinoic acid and PML signalling during APL. 
Although the specificity of ATO for PML–RARa-associated APL is clear, how it acts has remained 
contentious. ATO exerts a number of different effects that are to a degree concentration-dependent, inducing 
apoptosis at high concentrations and promoting differentiation at lower levels. Documented effects of ATO 
include interference with interactions between the SMRT co-repressor and nuclear receptors and induction 
of reactive oxygen species1. These activities could potentially contribute to the therapeutic effect of ATO in 
APL; however, it has been demonstrated that both PML–RARa and wild-type PML (but not wild-type RARa) 
are degraded in APL cells after ATO treatment. This supports the notion that the PML moiety is the primary 
target2. Subsequent studies in APL cells showed that ATO treatment leads to both PML and PML–RARa 
becoming highly modified by SUMO proteins, which are related structurally to ubiquitin, and that PML 
sumoylation can take place at Lys 65, 160 and 490 (ref. 3). A previous study suggested that only Lys 160 
SUMOylation is important for ATO-induced degradation of PML and PML–RARa, as this modification also 
mediates recruitment of the proteasome to PML nuclear bodies4. In this issue of Nature Cell Biology, 
Lallemand-Breitenbach et al5 and Tatham et al6 demonstrate that the RING finger ubiquitin E3 ligase 
RNF4/SNURF is critical for the SUMOylation-dependent ubiquitination and subsequent catabolism of PML. 
For PML to be ubiquitinated by RNF4, it must be modified by a polySUMO chain on Lys 160, which is 
specifically targeted by RNF4 through four tandemly arranged SUMO interaction motifs (SIMs) (Fig. 1; ref. 
6). ATO-induced differentiation was impaired when primary haematopoietic cells expressed a non-
degradable PML–RARa Lys 160 mutant, but not wild-type PML–RARa. Impaired differentiation in response 
to ATO also occurred in PML–RARa-positive primary haematopoietic cells transduced with a dominant-
negative mutant of RNF4 (ref. 5). Thus these results directly implicate RNF4-mediated PML–RARa 
degradation in the APL therapeutic response. 
An interesting aspect of these studies is that for arsenic to degrade PML effectively, SUMO-1 and SUMO-
2/3 are required. In this respect, it is noteworthy that a PML mutant lacking Lys 65 and Lys 490, but 
containing Lys 160 is still SUMO-1 conjugated after ATO treatment5. As SUMO-1 is unable to form polymers, 
in contrast to SUMO-2 or -3, it probably functions as a chain terminator. This notion is supported by the 
findings that the SUMO-1-modified PML K65/490R mutant has a molecular weight consistent with being 
polySUMOylated5 and that SUMO-1-'capping' can indeed occur7. Given that a SUMO-1 cap is not required 
for RNF4 to interact with and ubiquitinate polySUMO-2-modified PML6, attachment of SUMO-1 may serve 
some other purpose. One attractive possibility is that SUMO-1 termination of the Lys 160-attached chain 
inhibits its depolymerization by the SUMO-specific protease SENP6/SUSP1 (Fig. 1). Recent research has 
suggested that SENP6 acts preferentially against polySUMO chains comprising three or more SUMO-2/3 
moieties, and that SENP6 does not effectively deconjugate SUMO-1 (ref. 8). It remains to be seen whether a 





The upper pathway (A) represents the modification states that may exist between functional PML (top left) and its 
proteasomal degradation product. The PML 'pro- degradation' activities of as yet unspecified SUMO E3 ligases and 
RNF4 are opposed by the SUMO protease SENP6 and ubiquitin proteases, respectively. A balance is achieved in 
response to normal signalling that maintains the appropriate level of PML protein for a given cell type or developmental 
stage. RNAi-mediated knockdown of RNF4 leads to an accumulation of PML nuclear bodies enriched for SUMO 
proteins, supporting the notion that it has an important role in this process. In the lower pathway (B), ATO treatment 
alters the pathway kinetics (highlighted in red) to favour degradation of PML. The initial sequence of events that occur in 
response to arsenic remain to be determined but probably involves phosphorylation of residues at the N- and C-terminal 
regions of PML and perhaps also the removal of SUMO-1 at Lys 490. SUMO-1 is conjugated to PML at Lys 65 and the 
extended SUMO-2/3 chain on Lys 160, where it functions as a chain terminator. Arsenic-induced SUMOylation of Lys 65 
and Lys 160 is tightly coupled and SUMO-1 conjugation of Lys 65 may serve to recruit or stabilize the binding of a SUMO 
E3 ligase such as RanBP2, which contains a SIM that preferentially binds SUMO-1 (ref. 18). Furthermore, SUMO-1 
capping of the SUMO-2/3 chain on Lys 160 could diminish the effectiveness of SENP6, for which SUMO-1 is a poor 
substrate, thus favouring binding of RNF4 and subsequent ubiquitination and degradation of PML. 
 
Both articles have highlighted an important step linking PML SUMOylation and its degradation; however, 
the primary events through which arsenic directs this process remain to be uncovered. It is known that ATO 
activates several kinases and a requirement for MAP kinase phosphorylation of PML has been demonstrated 
in ATO-induced apoptosis9. Although the activities of MAP kinases in ATO-induced PML degradation were 
not specifically examined, the study found that PML phosphorylation in response to ATO enhanced its 
SUMOylation. This strongly suggests that ATO-induced PML phosphorylation is involved in the catabolic 
pathway, possibly as a trigger for an interaction with a known or as yet unidentified SUMO E3 ligase (Fig. 1). 
There may also be crosstalk between PML phosphorylation and SUMOylation, which mediates an interaction 
between PML and Pin1, a peptidyl-prolyl cis-trans isomerase that induces a conformational change in its 
substrate proteins. Recent research has shown that Pin1 activity is associated with PML degradation, 
although the potential role of Pin1 in mediating the effects of ATO has not yet been investigated. 
Interestingly, although Pin1 binding is dependent on phosphorylation of PML within its C-terminal region, 
PML SUMOylation blocks this interaction10. Given the link between PML SUMOylation and its degradation, 
this seems paradoxical but the study by Lallemand-Breitenbach et al. may provide an explanation5. They 
show that wild-type PML is SUMO-1 modified on Lys 490 and mutation of this residue enhances degradation 
of PML in response to ATO. This suggests a stabilizing effect of PML Lys 490 SUMOylation, possibly due in 
part to inhibition of Pin1-mediated degradation. Furthermore, mutation of the 'pro-degradation' PML Lys 65 
residue promotes Lys 490 SUMOylation, suggesting that SUMO modification of PML is subject to strict 
control by a variety of factors, whose activities can have antagonistic effects on its stability. 
Questions arising from the results presented in the two papers are whether RNF4 recognizes other 
polySUMOylated proteins and also, whether there are other proteins that contain multiple SUMO-interaction 
motifs. RNF4 has been reported to associate with a number of transcription factors and steroid hormone 
receptors11, 12, 13, 14, 15 but it is not known whether these interactions are mediated through the binding of 
polySUMO chains and/or related to the function of RNF4 as a ubiquitin E3 ligase. Although 
Schizosaccharomyces pombe contains two RNF4 homologues (Rfp1 and Rfp2), so far only RNF4 has been 
identified as possessing multiple SIMs in humans. However, a search of the Entrez database at the NCBI 
revealed the presence of a highly homologous 4  SIM-containing region in a predicted but as yet unverified 
isoform of a testis-specific RING protein encoded by the human RNF36 gene (accession number 
EAW77280). Interestingly, both RNF36 (TRIM69) and PML (TRIM19) are members of the tripartite motif 
(TRIM) family of RING domain-containing proteins and, given that mouse RNF36 localizes to PML nuclear 
bodies, the function of its human counterpart perhaps merits a more detailed investigation16. 
In conclusion, results presented in the two manuscripts identify RNF4 as a polySUMO chain-binding 
protein and also PML as a bona fide RNF4 target; this is the first example of a protein degraded by this 
SUMO-dependent ubiquitination pathway. Moreover, the findings by Lallemand-Breitenbach et al5 reinforce 
the scientific rationale for the use of low-dose ATO in differentiation therapy for PML–RARa-associated APL. 
However, given the role of PML as a growth/tumour suppressor17, the finding that ATO also targets PML 
presents a 'catch 22' situation with regard to its use as a treatment for cancers in general. Nevertheless, the 
success of ATO in APL therapy has provoked renewed interest in its use and a large number of clinical trials 
investigating its potential in haematological malignances and solid tumours are currently underway or 
recently have been completed.1 This, along with the development of other organic arsenic compounds could 
well see the emergence of new applications for this semi-metal in the wider range of cancer therapies. 
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